Cipla receives 12 observations from USFDA inspection of its Goa facility

Cipla announced that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at its Goa manufacturing facility from 16-27 September 2019.

The inspection ended with 12 observations, none of which are related to data integrity. The Company will respond to the agency within the stipulated timeline.

Powered by Capital Market - Live News